TransMedics Group (NASDAQ:TMDX) Trading Down 6.1%

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price fell 6.1% on Wednesday . The company traded as low as $87.56 and last traded at $87.65. 447,535 shares traded hands during trading, a decline of 34% from the average session volume of 681,154 shares. The stock had previously closed at $93.31.

Analyst Ratings Changes

A number of brokerages have weighed in on TMDX. JPMorgan Chase & Co. increased their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer raised their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Piper Sandler started coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price objective for the company. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $102.00.

TransMedics Group Trading Down 3.5 %

The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The firm’s 50 day simple moving average is $82.97 and its 200 day simple moving average is $72.98.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same period in the previous year, the firm earned ($0.21) earnings per share. The firm’s revenue for the quarter was up 158.6% on a year-over-year basis. On average, analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 4,000 shares of TransMedics Group stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. Insiders have sold a total of 119,408 shares of company stock worth $10,182,881 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds have recently modified their holdings of the business. Ancora Advisors LLC bought a new stake in shares of TransMedics Group during the 1st quarter valued at $38,000. First Horizon Advisors Inc. boosted its holdings in shares of TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after buying an additional 169 shares in the last quarter. Belpointe Asset Management LLC boosted its holdings in shares of TransMedics Group by 51.6% during the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock valued at $42,000 after buying an additional 190 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of TransMedics Group by 595.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock valued at $50,000 after buying an additional 512 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of TransMedics Group during the 4th quarter valued at $47,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.